BBIO - BridgeBio draws Buy rating at Cantor citing 100% upside
2023-10-24 15:34:36 ET
More on BridgeBio Pharma
- BridgeBio: Bets Acoramidis As The Pfizer Spoiler
- BridgeBio: Positive Updated Acoramidis Data May Not Imply Further Upside
- BridgeBio Pharma to issue 9.2M shares through PIPE financing
- BridgeBio heart drug meets primary endpoint in late-stage trial
- Seeking Alpha’s Quant Rating on BridgeBio Pharma
For further details see:
BridgeBio draws Buy rating at Cantor citing 100% upside